Moderna TX Inc.
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| infectiousDisease | ×0.90 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 4 disclosed transactions, Moderna TX Inc. concentrates its licensing activity in InfectiousDisease. Moderna TX Inc. pays a 0.90x discount to market median, with the strongest premiums in InfectiousDisease (0.90x). Their most common deal structure is Collaboration, with an average disclosed value of $397M. Most recent activity: 2025.
Premium by therapeutic area
How Moderna TX Inc. pays relative to peer medians in each TA
Pipeline coverage & gaps
Moderna TX Inc. has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 4 | $353M | $397M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | mRNA-1018 | CEPI | H5 pandemic influenza | phase_3 | $54M | $54M |
| 2025 | mRNA pandemic influenza vaccines | HHS | pandemic influenza | phase_3 | $590M | $590M |
| 2025 | mRNA-1018 | HHS/BARDA | pre-pandemic influenza (H5, H7, and additional subtypes) | phase_2 | $590M | $766M |
| 2024 | Group 1 H5NX mRNA pandemic influenza vaccine | RRPV | pandemic influenza H5NX | preclinical | $176M | $176M |
How this is computed
For each Moderna TX Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.902, clamped to [0.7, 1.5].